Bio-Rad plans to drive adoption of Stilla's all-in-one Nio+ dPCR system while also incorporating its own assays to expand the menu.
Cell-Free DNA Analysis Predicts Preeclampsia Risk
Researchers used a new computational framework to predict preeclampsia risk from low-coverage whole-genome sequences generated on cell-free DNA found in maternal blood.
Judge Temporarily Blocks NIH Grant Indirect Cost Cut, Universities File Separate Challenge
A coalition of universities has launched a lawsuit in the District of Massachusetts against the NIH and the Department of Health and Human Services, joining one filed Monday by state attorneys general.
Between 20 percent and 25 percent of 10x Genomics' revenues are tied to NIH-funded projects, and grant money heading 10x's way was already expected to be down.
Latent Labs Emerges From Stealth With $50M in Funding for AI-Powered Protein Design
The firm is developing generative AI software to speed drug discovery through de novo protein design.
Grail Stock Surges on Quest Diagnostics Integration of Galleri MCED Test
Physicians in the US can now order the blood-based multi-cancer early detection assay through Quest.
The firm said that it does not expect NIH spending cuts, but its internal modeling shows the potential loss of 2025 revenues topping out at around $15 million.